The invention relates to stabilised solid pharmaceutical compositions comprising a GLP-1 agonist. The invention further relates to processes for the preparation of such compositions, and their use in medicine.

This disclosure provides a dry powder formulation of free amino acids with an acceptable and even good taste profile.

This disclosure provides a dry powder formulation of free amino acids with an acceptable and even good taste profile.

This disclosure provides a dry powder formulation of free amino acids with an acceptable and even good taste profile.

Methods and formulations of modified release amino acids are provided for the treatment or management of diseases defined by impaired amino acid metabolism, with improved pharmacokinetics, metabolism and utilization.

Methods and formulations of modified release amino acids are provided for the treatment or management of diseases defined by impaired amino acid metabolism, with improved pharmacokinetics, metabolism and utilization.

Methods and formulations of modified release amino acids are provided for the treatment or management of diseases defined by impaired amino acid metabolism, with improved pharmacokinetics, metabolism and utilization.

The invention provides compositions and methods to treat prediabetes. In particular, the inventor has discovered that particular combinations of diverse types of antioxidants have synergistic and surprising effects for use against prediabetes. The composition includes: a plurality of heteroatom-based antioxidants having the formula X—CH.sub.2—CH(R)—(CH.sub.2).sub.m—Z; a plurality of antioxidants with a conjugated segment; an antioxidant that is a flavan-3-ol; and an antioxidant that contains a disulfide bond. The antioxidants are chosen such that at least one has a pro-oxidative effect.

The invention provides compositions and methods to treat prediabetes. In particular, the inventor has discovered that particular combinations of diverse types of antioxidants have synergistic and surprising effects for use against prediabetes. The composition includes: a plurality of heteroatom-based antioxidants having the formula X—CH.sub.2—CH(R)—(CH.sub.2).sub.m—Z; a plurality of antioxidants with a conjugated segment; an antioxidant that is a flavan-3-ol; and an antioxidant that contains a disulfide bond. The antioxidants are chosen such that at least one has a pro-oxidative effect.

The invention provides compositions and methods to treat prediabetes. In particular, the inventor has discovered that particular combinations of diverse types of antioxidants have synergistic and surprising effects for use against prediabetes. The composition includes: a plurality of heteroatom-based antioxidants having the formula X—CH.sub.2—CH(R)—(CH.sub.2).sub.m—Z; a plurality of antioxidants with a conjugated segment; an antioxidant that is a flavan-3-ol; and an antioxidant that contains a disulfide bond. The antioxidants are chosen such that at least one has a pro-oxidative effect.